The Canadian insurer's Ned Pojskic says early claims data shows fewer asthma and arthritis claims, and generic semaglutide costs about 65% less than the brand.
Recap by typeshit. Full story at Benefits and Pensions Monitor.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
The analysis weighs whether Viking can become the third company, after Lilly and Novo Nordisk, to win approval for a GLP-1 weight loss drug.
The tablets would release the peptides in the colon, aimed at left-sided ulcerative colitis. Neither peptide is FDA-approved, and delivery tests so far used budesonide, not these peptides.
Loading…